

Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry*

Etienne Caron‡||, Daniel J. Kowalewski§, Ching Chiek Koh‡, Theo Sturm‡, Heiko Schuster§, and Ruedi Aebersold‡¶||

The myriad of peptides presented at the cell surface by class I and class II major histocompatibility complex (MHC) molecules are referred to as the immunopeptidome and are of great importance for basic and translational science. For basic science, the immunopeptidome is a critical component for understanding the immune system; for translational science, exact knowledge of the immunopeptidome can directly fuel and guide the development of next-generation vaccines and immunotherapies against autoimmunity, infectious diseases, and cancers. In this mini-review, we summarize established isolation techniques as well as emerging mass spectrometry-based platforms (*i.e.* SWATH-MS) to identify and quantify MHC-associated peptides. We also highlight selected biological applications and discuss important current technical limitations that need to be solved to accelerate the development of this field. *Molecular & Cellular Proteomics* 14: 10.1074/mcp.O115.052431, 3105–3117, 2015.

The immunopeptidome is referred to as the collection of peptides associated with and presented by major histocompatibility complex (MHC) molecules (1–11). MHC-associated peptides are recognized by T lymphocytes that are in turn activated to eliminate abnormal cells such as pathogen-infected and cancer cells. These immune peptides are divided in two classes: MHC class I and class II peptides that are distinguishable by (1) their structure, (2) the intracellular pathways by which they are generated, and (3) the type of T lymphocytes that recognize them, reviewed in (12, 13). In brief, MHC class I peptides are predominantly 9–12 amino acids in length or slightly longer (14–17). Class I peptides are generated mainly following degradation of intracellular pro-

teins by the ubiquitin-proteasome system and are recognized by cytotoxic CD8+ T cells (18). MHC class II peptides are 10–25 amino acids in length, derived mainly from protease-mediated degradation of endocytosed proteins of extracellular origin, and are recognized by helper CD4+ T cells. The tissue/cell type distribution also differs for class I and class II peptides: Class I peptides are presented on virtually any nucleated cell, whereas peptides displayed by class II molecules are found on a subset of specialized immune cells such as dendritic cells, macrophages, and B lymphocytes. In recent years, there has been, however, a rapid increase in the number of nonhematopoietic cell types suggested to present peptides on MHC class II molecules (19).

In the human population, the complexity of the MHC immunopeptidome is amplified by the very large genetic pool coding for structurally different class I and class II MHC molecules, termed human leukocyte antigen (HLA) molecules (20). In fact, the HLA genes constitute the most polymorphic gene cluster in the human genome. The allelic diversity often alters the structure and specificity of the peptide-binding sites of the HLA molecules (21, 22). Consequently, each HLA allotype associates with a specific set of peptides bearing conserved amino acids known as “residues” or HLA binding motif (23, 24). The human genome comprises over 10,000 different HLA allelic forms (<http://www.ebi.ac.uk/imgt/hla/stats.html>; April 2015), and each person expresses up to six different classical class I allotypes and typically eight different class II allotypes, resulting in a huge HLA peptidomic complexity at the population level (25).

Pioneered by Donald Hunt in the early 1990s, analyses of MHC-associated peptides by data-dependent analysis (DDA) mass spectrometry (MS) have yielded groundbreaking knowledge about the peptide binding motifs of MHC molecules (26). Thanks to the astonishing progress in MS-based technologies over the last decade, hundreds to thousands of MHC-associated peptides can now be identified in a single measurement using optimal biological model systems. More recently, targeted MS techniques have emerged as robust approaches to accurately and reproducibly quantify the dynamics of antigen presentation (27). As a result of such emerging technologies, a better understanding of our immune system as well

From the ‡Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland; §Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany; ¶Faculty of Science, University of Zurich, Zurich, Switzerland

Received June 1, 2015, and in revised form, September 23, 2015
 Published, MCP Papers in Press, October 19, 2015, DOI 10.1074/mcp.O115.052431

Author contributions: E.C., D.J.K., C.K., T.S., H.S., and R.A. wrote the paper.

as clinical applications are expected. In this mini-review, we aim at (1) describing key technical considerations in the selection of appropriate model systems for the exploration of immuno-peptidomes, (2) summarizing established methods for the isolation of MHC-associated peptides for mass spectrometric analysis, (3) providing an up-to-date description of standard and emerging MS techniques, and (4) discussing future directions that, if explored, will advance the field.

Considerations in the Selection of Model Systems—At the genomics level, any living organism can be investigated following robust and efficient extraction of DNA. In contrast, not every biological model system is compatible with the analysis of the immuno-peptidome. In principle, class I peptides are expected to be detectable on most cell and tissue types in mammals, as genes coding for MHC class I molecules are expressed in virtually any nucleated cell in jawed vertebrates. However, many technological limitations, as described below, have yet to be overcome (*e.g.* isolation of peptides, dynamic range of mass spectrometers, software tools) to reach robust and comprehensive analysis of MHC I immuno-peptidomes from any mammalian cell type. New methods for the investigation of class I peptides would also be beneficial for the analysis of class II immuno-peptidomes as both classes of peptides share generally similar technical limitations.

Currently, suitable model cell lines or tissues for immuno-peptidome analysis have to express high levels of endogenous MHC molecules. Determining the absolute number of cell surface MHC molecules by flow cytometry and/or mass spectrometry is therefore an important initial step when establishing a new model system (28, 29). On average, we noted from pertinent literature reports that the usage of at least $\sim 5 \times 10^8$ cells expressing $\sim 2 \times 10^5$ MHC molecules per cell was a minimum requirement for the exploration of cellular immuno-peptidomes (3, 4). Cell lines expressing low levels of endogenous class I molecules (*e.g.* C1R cells) but high levels of transfected MHC molecules, either soluble or membrane bound, have also been used in many immuno-peptidomics studies (30–34). This property makes these cells particularly attractive for the analysis of peptides presented by individual class I allotypes as the overexpression provides the flexibility required for the exploration of the allotypes (35, 36) (Fig. 1, *upper panel*).

Analysis of MHC class I and II peptide ligands from cells isolated in mouse primary tissue were reported with limited success given the high number of mice needed to perform an experiment (37–40). In terms of translational potential, primary human tissues are highly attractive (Fig. 1, *upper panel*). In general, ~ 1 g of tissue is required to detect hundreds to thousands of MHC class I peptides (41). In fact, the amount of starting material needed for the detection of high numbers of peptides is inversely proportional to the expression levels of MHC molecules. For instance, if specific tumor specimens express high levels of MHC molecules, much less material is usually needed to detect high numbers of peptide se-

quences. However, specific and rigorous assays determining the exact amount and quality of the tissue required for such analyses have yet to be documented to translate the approach more effectively to the clinic.

Isolation of MHC Class I and Class II peptides—In the early days, papain proteolytic digestion was moderately successful for the isolation of MHC-associated peptides (42–44). However, this technique has not been widely used because of the large quantities of starting materials required. In the early 1990s, three main techniques to extract MHC-associated peptides were developed: (1) strong acid elution of MHC class I and II peptides from whole-cell lysate using trifluoroacetic acid (45–47), (2) mild acid elution (MAE) of class I peptides (not class II peptides) from the cell surface (48), and (3) immunoaffinity purification (IP) of the class I and II MHC peptide complexes from detergent solubilized cell lysates followed by the release of ligands from the isolated complexes (49) (Fig. 1, *middle panel*).

Nowadays, MAE and IP are the best established and most widely used methods, both still requiring large amounts of starting material (typically 2×10^8 to 1×10^{10} cells). Until recently, MAE was used to isolate MHC class I peptides from various cell lines, bone-marrow-derived dendritic cells, and primary thymocytes (5, 38, 39, 48, 50). The MAE approach is cell-surface-specific and can be repeated over time from the same cell population, *e.g.* to isolate newly generated MHC class I peptides. A significant proportion of peptides is, however, nonspecific for the MHC class I molecule (38, 39). In fact, by comparing the number of MAE-extracted peptides from wild-type and $\beta 2$ -microglobulin knockout cells — the latter expressing virtually no detectable level of cell surface MHC class I molecules — about 40–60% of the identified peptides were determined to be contaminants, *i.e.* non-MHC class I-derived.

Two main advantages can be attributed to the IP strategy: (1) the high specificity of the extraction process for peptides associated to MHC molecules and (2) its flexibility (Fig. 1, *middle panel*). In fact, this method can be used for the isolation of both class I and class II MHC peptides from a range of biological sources such as cell lines, primary tissues and plasma (36, 51–53). Moreover, up to $\sim 90\%$ of immunopurified peptides were reported to be specific for the MHC molecules (51, 54).

Using the standard IP protocol, cells are first treated and lysed with a nondenaturing detergent (53). MHC peptide complexes are then precipitated by applying the complex lysate to an affinity column coupled with monoclonal antibody (mAb) specific for a certain MHC class or allotype (53, 55). Both cell surface and intracellular MHC molecules are precipitated. HPLC fractionation or filtering is generally used following the IP (and MAE) preparation to separate peptides from larger complex components. Due to high consumption of affinity matrix, this isolation technique typically requires in-house production of mAb from hybridoma cell lines. Of note, papain




FIG. 1. Performance profiles of general resources for the analysis of MHC immunopeptidomes. In the radar charts, variables are represented on axes by a spoke. The highest value on the scale (10) indicates top performance. The lowest value on the scale (0) indicates bad performance. (Upper panel) Cell lines, primary mouse and human tissues represent best-established model systems for the analysis of immunopeptidomes. “Transfectants” refers to cell lines expressing low levels of endogenous MHC molecules but high levels of transfected MHC molecules. (Middle panel) IP and MAE are two established methods for the isolation of MHC-associated peptides. Strong acid elution from whole cell lysis is represented by the dotted green spoke as the performances are hypothetical. (Lower panel) Application of DDA, targeted and DIA MS for the analysis of immunopeptidomes. MS2 spectra (DDA) and chromatographic ion traces (targeted and DIA) are illustrated.

digestion has also been used in combination with the IP method to cleave and subsequently isolate cell surface MHC-peptide complexes (50, 56).

The IP method is highly specific but presumably comes with the cost of a very low yield, *i.e.* ~0.5–3% as reported by Hassan *et al.* (57). This study used a state-of-the-art, quantitatively accurate MS technique—termed selected or multiple reaction monitoring (SRM or MRM, respectively)—to quantify all losses of HLA class I peptides during sample processing. The authors showed, for the first time, that the immunopurification step was at the origin of significant losses during sample handling. Whether the yield of the IP approach is highly variable between different laboratories has yet to be reported. Nevertheless, this study stressed the need for the development of new and more efficient methodologies for the isolation of MHC-associated peptides and for the accurate quantification of stepwise yields of the procedure.

Thus, current isolation techniques are suitable for the analysis of immuno-peptidomes from various biological model systems. However, the field would greatly benefit from additional technical reports as well as standardized protocols leading to comparable results between different laboratories.

MS-Based Platforms in Immuno-peptidomics—Over the last decade, our ability to identify and quantify MHC-associated peptides using MS has greatly benefitted from progress made in the field of MS-based proteomics (58, 59). Three types of MS data acquisition methods are now available for the measurement of MHC-associated peptides: (1) DDA, (2) targeted data acquisition, and (3) data-independent acquisition (DIA) (60). DDA is a well-established and a widely used method for large-scale identification of MHC-associated peptides (61–63). In contrast, the targeted and the DIA approaches are still emerging, and both techniques are expected to offer unprecedented advantages in terms of reproducibility and quantitative accuracy for the measurement of MHC peptide ligands across multiple samples, as recently demonstrated in proteomics (64–66). The following section describes the principles of these three data acquisition methods with a particular focus on the measurement of class I MHC peptides.

Mapping Immuno-peptidomes in DDA Mode—Over the last decade, most MS-based peptidomic studies were carried out using DDA (also known as discovery-based or shotgun MS) to maximize the amount of information acquired within an experiment. In fact, the latest generation of MS instruments—capable of high-resolution and accurate mass measurements (*e.g.* Q-Exactive or quadrupole TOF) (67, 68)—enables the identification of hundreds to thousands of MHC class I or class II peptides within several hours (62). In DDA mode, ionized MHC peptide ligands (precursor ions) are first detected in a survey scan (MS1 scan) (Fig. 2, upper panel). The most abundant precursor ions detected in the precursor ion scan (TopN) are then selected for fragmentation using collision-induced dissociation (CID), beam-type higher-energy

CID¹ (HCD) or electron-transfer dissociation. The resulting fragment ions (product ions) are finally detected and recorded as fragment ion spectra (MS2 spectra). For sequence identification, the recorded MS2 spectra are searched against a protein database using commercial and/or open-source automated search engines (69, 70). For MHC class I-associated peptides, ~10% of the acquired MS2 spectra can be confidently assigned (false discovery rate <1%) to a peptide sequence (54). The exact proportion of confidently assigned MS2 spectra might be, however, largely laboratory dependent and might depend on the acquisition parameters of the instrument used (*e.g.* length of measurement, threshold settings, and amount of samples). The relatively low identification success rate of ~10% (as opposed to ~50% for peptides generated by tryptic digestion of intact proteins) can be attributed to the shortness and the nontryptic nature of MHC class I peptides. In fact, many class I peptides are inefficiently ionized due to the lack of basic amino acid residues, and standard fragmentation methods generate hardly predictable, information-poor MS2 spectra (71). Thus, only a small fraction of the acquired MS2 spectra contain sufficient information for the correct assignment of the peptide sequence. To boost the identification of class I peptides, new ionization and fragmentation techniques, as well as novel software tools optimized for MHC peptide ligands, would need to be developed.

Along these lines, Ternette *et al.* recently found that 5% of dimethyl sulfoxide in liquid chromatography solvents enhanced the electrospray ionization of HLA class I peptides, improving the total ion count by approximately twofold (personal communication) (72, 73). However, the effect of enhancing electrospray ionization and sensitivity might depend on the type of emitter source as well as specific parameters such as voltage, temperature, and gas flow. Interestingly, a gain in HLA class I peptide identification was also found by introducing a novel fragmentation method termed “electron-transfer/higher-energy collision dissociation” (54). With electron-transfer/higher-energy collision dissociation, Mommen *et al.* found that 39% of the acquired MS2 spectra led to high-confidence HLA class I peptide assignments (54). This method generates the fragment ions induced by ETH (c/z) and HCD (b/y) and combines them in a single spectrum (74, 75). The authors directly attributed the better performance of electron-transfer/higher-energy collision dissociation for the identification of HLA class I peptides (*i.e.* approximately threefold increase)—in comparison to CID, HCD, and electron-transfer dissociation—to the more extensive backbone fragmentation

¹ The abbreviations used are: CID, collision-induced dissociation; CV, coefficient of variation; DDA, data-dependent acquisition; DIA, data-independent acquisition; HCD, beam-type higher-energy CID; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; HRM, hyperreaction monitoring; IP, immunoaffinity purification; mAb, monoclonal antibody; MHC, major histocompatibility complex; MRM, multiple reaction monitoring; MS, mass spectrometry; PRM, parallel reaction monitoring; SRM, selected reaction monitoring.




FIG. 2. Mass spectrometer configurations used for the analysis of MHC-associated peptides. All settings comprise isolation and fragmentation of precursor ions and recording of the mass to charge ratio of MS2 fragment ions in a mass analyzer. (Upper panel) In DDA MS, only the most abundant precursor ions (TopN) per MS1 scan are selected for consecutive isolation and fragmentation. A linear ion trap, an Orbitrap, or a TOF analyzer is used for the high-throughput acquisition of MS1 and MS2 spectra. (Middle panel) In targeted MS, S/MRM exploits the capability of a triple quadrupole to screen a list of transitions (tr), i.e. precursor-fragment ion pairs. The transitions are monitored over time to yield ion traces corresponding to the peptides of interest. PRM experiments are conducted using an Orbitrap-type high-resolution and

and the generation of information-rich MS² spectra. They also noted that the statistical validation algorithm, Percolator (76), performed approximately twofold better than the standard target–decoy approach (77), irrespective of the fragmentation method used.

Although MS-based immuno-peptidomics has greatly benefited from enormous advances in high-resolution instrumentation in recent years, it is now apparent that mass spectrometers operated in DDA mode are less well suited for solving problems that require the comparison of comprehensive, quantitative, and reproducible datasets across many samples or conditions. In fact, Michalski *et al.* reported that while 100,000 peptide features were recorded from a complex digest of cell lysate, only 16% were selected for fragmentation (referred as undersampling) even though the experiment was performed on a fast scanning LTQ-Orbitrap Velos mass spectrometer (78). Moreover, the selection of the precursor ions in DDA mode follows a simple intensity-dependent heuristics, leading to stochastic isolation of precursor ions for fragmentation and therefore irreproducible peptide identification when the same sample is repeatedly analyzed (79–81). In fact, ~20% of the selected HLA class I peptides were shown to vary between replicate analyses of the same sample (82). Targeted MS strategies can alleviate this limitation. Their principles are described below with a particular focus on S/MRM and parallel reaction monitoring (PRM).

Identification and Quantification of MHC-Associated Peptides in Targeted Data Acquisition Mode—Targeted quantitative proteomics was acknowledged as the method of the year in 2012 by *Nature Methods* (64, 83). In contrast to DDA, targeted data acquisition methods offer high specificity, sensitivity, reproducibility, quantitative accuracy, and a wide dynamic range (approaching five orders of magnitude) for the measurement of peptides (84–86) (Fig. 1, lower panel). State-of-the-art targeted methods are mainly performed in S/MRM and PRM mode on a low-resolution triple quadrupole and a high-resolution quadrupole Orbitrap mass spectrometer, respectively (Fig. 2, middle panel) (84, 86). Such MS-based targeted platforms require *a priori* knowledge of the molecular targets. These techniques are routinely used within the proteomics community but were only recently applied for the sensitive detection and the robust quantification of MHC class I peptides (27, 37, 57, 87, 88).

S/MRM is considered the gold standard quantification method for predefined sets of target peptides (84). The method exploits the capability of the first and the third quadrupole in a triple quadrupole mass spectrometer to act as mass filters for the iterative isolation of a precursor ion and a

fragment ion derived from the targeted precursor—also known as a transition (Fig. 2, middle panel). In a typical S/MRM experiment, the signal of three to six transitions per targeted MHC peptide ligand is recorded over the chromatographic elution profile of the targeted peptide. This type of targeted data acquisition results in a peak group (coeluting fragment ion traces) that is subsequently analyzed using software tools such as Skyline (89), mProphet, and mQuest (90, 91). Importantly, selection of optimal transitions has to be carried out before an S/MRM experiment, typically involving the use of synthetic peptides, that optionally are heavy isotope labeled (92–94). Therefore, optimization of S/MRM transitions requires significant efforts. On a quadrupole orbitrap mass spectrometer operated in PRM mode, this rather time-consuming preacquisition selection process is not required since all fragment ions of the targeted peptide and potentially coselected contaminating peptides are recorded for each precursor-ion charge state (Fig. 2, middle panel)—the selection of optimal fragment ion traces is therefore carried out postacquisition for peptide identification and quantification (95). Synthetic peptides are used in proteomics to optimize the collision energy of individual transitions. In this regard, previous studies showed that the sensitivity gain resulting from optimizing the collision energy for each transition was about twofold compared with the signals obtained from more generic collision energies computed according to the mass of the targeted precursor (92, 94, 96–98). This optimization process could therefore be particularly beneficial for the detection of low-abundance MHC-bound peptides (27, 88).

For the reproducible and accurate quantification of tryptic peptides in complex proteome digests, the S/MRM technique has been shown to reach a high dynamic range of about five orders of magnitude, as well as excellent interlaboratory reproducibility, with a median coefficient of variation (CV) of ~5% (99). Similar analytical performances were also observed using the PRM approach (100–102). Nevertheless, such targeted techniques are still emerging in immuno-peptidomics, and only a few studies have used S/MRM or PRM for the relative and absolute quantification of MHC peptides (8, 27, 36, 37, 57, 87). For instance, the group of Purcell demonstrated in a technical note that the limit of detection for the model peptide SIINFEKL was in the attomol range using the S/MRM technique (37). In addition, S/MRM and PRM were recently applied—in combination with MHC-monomers loaded with heavy-labeled peptides—to quantify the yield of the IP method, as mentioned above (57). Importantly, intra- and interlaboratory studies measuring the limit of quantification, limit of detection, CV, and chromatographic reproduc-

accurate mass spectrometer (e.g. Q-Exactive). All MS² product ions derived from predefined peptides (MS¹ precursors) are recorded over time to generate the ion chromatographic traces. (Lower panel) HRM and SWATH MS are two fundamentally similar data-independent acquisition methods employing an Orbitrap-type and a quadrupole TOF high-resolution accurate mass spectrometer, respectively. In DIA mode, multiplexed ion traces are acquired by repeatedly cycling through predefined consecutive precursor isolation windows (originally 32 × 25 Th) and by monitoring all fragment ions.

ibility have yet to be conducted from a large set of MHC peptide ligands.

S/MRM and PRM are two fundamentally similar approaches considered to be highly robust for the sensitive, reproducible, and accurate quantification of peptides. Nevertheless, both techniques are limited by their capacity to detect hundreds of peptides per sample injection and thus are not ideally suited to comprehensively quantify immuno-peptidomes. To overcome this limitation, new MS methods, collectively known as DIA, have recently emerged and should expedite the deciphering of immuno-peptidomes. Below, we focus on the SWATH-MS sequential window acquisition of all theoretical mass spectra (SWATH-MS) technology (103), one of the DIA strategies that was very recently applied to analyze immuno-peptidomes from a range of biological sources (82).

Digital Mapping of Immuno-peptidomes in DIA Mode—DIA is an unbiased MS technique that combines the advantages of DDA and S/MRM (104). Since the introduction of its concept in 2004, several DIA strategies have been described and were reviewed in detail (66, 105–107). In essence, this acquisition mode converts all peptides in a physical sample into a permanent digital map composed of multiplexed MS² spectra derived from the fragmentation of all precursor ions. Data collection is therefore comprehensive and quantitative information can be mined retrospectively (Fig. 1, lower panel). More recently, SWATH-MS was introduced as a new DIA method for the consistent, reproducible, and quantitatively accurate measurement of proteins across multiple samples (103, 108–116). The SWATH-MS and the SWATH-like hyper-reaction monitoring (HRM) techniques provide S/MRM-like performance in terms of reproducibility and quantitative accuracy and were implemented in a fast-scanning, high-resolution quadrupole time-of-flight and a quadrupole orbitrap mass spectrometer, respectively (Fig. 2, lower panel) (68, 117). In SWATH or HRM mode, the instrument cycles repeatedly through fixed or variable adjacent precursor isolation windows (typically 32 windows of 25 *m/z* covering 400–1200 *m/z*) over the course of chromatographic elution, thus fragmenting all coeluting precursor ions in each window recording multiplexed fragment ion spectra of all peptides in a user-defined retention time *versus* mass to charge window.

To extract quantitative information from such digital SWATH-MS data, high-quality assay libraries are required (109, 111). Such libraries contain retention-time and fragmentation information of the peptides to be quantified. Assay libraries are generated from native and/or synthetic peptides using a SWATH-compatible mass spectrometer operated in DDA mode. Very recently, assay libraries were successfully employed for the high-throughput measurement of HLA-associated peptides by SWATH-MS (82). Caron *et al.* demonstrated, for the first time, the feasibility of an international effort to build standardized HLA allele-specific peptide spectral and assay libraries, which were used to extract quantitative information from digital SWATH maps acquired in differ-

ent laboratories. Importantly, the authors demonstrated that the SWATH method clearly outperformed the DDA approach for the reproducible identification of HLA class I peptides across several technical replicates. In addition, Caron *et al.* showed that (1) ~81% of HLA class I peptides present in an assay library could be reliably extracted from a quantitative SWATH map in a cell-type-independent manner, (2) narrowing the size of the windows by 2.5-fold (*i.e.* from 25 Da to 10 Da width each) resulted in a ~13% increase in the identification of class I peptides, and (3) the dynamic range of peptides quantified by SWATH-MS in different cell types, based on their signal intensity, was about 3–4 orders of magnitude. Moreover, HLA peptide ligand spectral and assay libraries were stored by class and allele in the public SWATH Atlas database (<http://www.swathatlas.org/>, also covering libraries for proteome analysis), providing an initial transparent framework to collect, organize, and share immuno-peptidomic data. Thus, the workflow and the computational and data resources presented in that study was a first step toward highly consistent, reproducible, and quantitatively accurate measurements of immuno-peptidomes across multiple samples.

Although the development of DIA/SWATH-based technologies is an important advance in the field, the detection and quantification of low abundant MHC-associated peptides still remain a major challenge. In this regard, the limit of detection and limit of quantification of SWATH-MS for MHC peptide samples have not been reported yet but were recently determined to be in the low-femtomole to mid-attomole range for high complexity samples across multiple laboratories (Collins *et al.* manuscript in preparation) (103). The capability of current software tools (*e.g.* OpenSWATH, Peakview, Spectronaut, Skyline) to reliably discriminate real signals from interfering peaks in complex DIA-windows is also considered as an important limitation. Another limitation is the nonconventional fragmentation of MHC peptides, resulting in information-poor MS² spectra. This is a challenge for the creation of high-quality HLA allele-specific peptide assay libraries in which both the quality and quantity of fragment ions are important. Computational analysis of fragmentation patterns for MHC peptides using publically available immuno-peptidomics datasets might help in this regard (118). Over the next ten years, both the selectivity and sensitivity of new DIA/SWATH mass spectrometers are expected to improve quite significantly. For instance, next-generation mass spectrometers might cycle at extreme speed through high numbers of very small precursor isolation windows (*e.g.* 1 *m/z*) over the course of chromatographic elution. Such performance in SWATH-MS would dramatically reduce the presence of interfering peaks and would facilitate the reliable identification and quantification of low abundant peptides. By continuously expanding HLA-allele-specific peptide assay libraries and by improving the performance of computational frameworks, it can also be expected that more HLA-associated peptides will

be confidently extracted from DIA/SWATH data in the future. Moreover, robust untargeted analysis of DIA immuno-peptidomics data will enable reproducible analysis of MHC immuno-peptidomes without the need for spectral and assay libraries, as recently shown for DIA proteomics data (119).

Application of DDA-, Targeted- and DIA-Based Immuno-peptidomics in Basic and Translational Studies—Over the last decade, the methods described above were applied in various biological contexts for the analysis of class I and class II MHC peptides. MS-based approaches, together with MHC peptide ligand prediction algorithms (e.g. SYFPEITHI, Net-MHC, smm) (120–122) were particularly helpful to better understand the molecular mechanisms that process cellular proteins into the immuno-peptidome as well as for the detection of disease-related peptides and phosphopeptides that could be used for the rational design of immunotherapeutic interventions (123–125). Since a comprehensive survey of the literature is not within the scope of this mini-review, we focus below on selected landmark papers and applications of outstanding interest.

Large-scale identification of MHC peptide ligands by MS took off in 2004 with the analysis of more than 200 naturally presented HLA-B*1801 peptides (31). In this seminal paper, Hickman *et al.* sequenced peptide ligands of secreted HLA molecules from a transfected human B cell line using DDA MS. This study indicated, for the first time, that HLA class I peptide ligands were encoded by any gene, suggesting that any protein from any cellular compartment could potentially contribute to the composition of the MHC class I immuno-peptidome. This basic notion was then further supported by additional DDA-based studies, collectively indicating that the MHC class I immuno-peptidome conveys to the cell surface an integrative view of gene regulation (30, 35, 39, 51, 123, 126–136).

The journal *Science* highlighted cancer immunotherapy as the “2013 Breakthrough of the Year” (137). In fact, compelling clinical results have shown that antibody-based checkpoint blockade therapy can restore the function of T lymphocytes to eradicate tumor cells (138). By integrating exome sequencing, MHC peptide ligand prediction algorithms and targeted MS, Gubin *et al.* recently identified tumor-specific mutant MHC class I peptides as targets of this form of immunotherapy (88). Proteogenomics approaches (139, 140) using DDA MS were also recently used for the identification of mutant as well as polymorphic MHC class I peptides (5, 51, 141–144). Notably, the detection of tumor-specific mutant MHC peptides has not been achieved yet using DIA MS. If tested and validated, DIA MS could, nevertheless, represent a robust approach in the clinic for the development of next-generation T-cell-based cancer vaccines as well as for the stratification of patients who might best benefit from checkpoint blockade immunotherapy (138, 145, 146).

Rapid, robust, and inexpensive detection of tumor-specific and pathogen-derived HLA peptides from low amounts of

starting material is expected to have a strong impact on the development of vaccines against cancers as well as deadly infectious diseases such as tuberculosis, HIV and malaria (147, 148). MS-based technologies have matured enough to facilitate the analysis of self-immuno-peptidomes but might still fall short of deciphering the full repertoire of HLA peptide ligands encoded by the genes of a pathogen or tumor-specific alleles. In fact, state-of-the-art mass spectrometers enable, at best, the detection of a few dozen pathogen-derived HLA peptides (*i.e.* for vaccinia virus, HIV, hepatitis C virus, human papillomavirus, and human respiratory syncytial virus) per experiment using optimal *in vitro* model systems (27, 72, 132, 147, 149–151). Interestingly, the development of a high-throughput

cytotoxic T cell-based platform for epitope discovery was recently reported (152). The results generated by this technology indicated that the repertoire of self-HLA peptides has been clearly underestimated by MS studies. Thus, benchmarking studies should be conducted to clarify whether or not the emerging MS methods described herein already provide the required sensitivity for the measurement of the most relevant immunogenic T-cell epitopes.

Data Sharing and Future Directions—The field of MS-based proteomics has progressed at an exceptionally fast pace over the last decade and the technical progress has also been highly beneficial for the MS-based measurement of MHC-associated peptides. As a consequence of new technologies, hundreds of thousands of different HLA class I and class II peptides are expected to be sequenced in the future given the extreme diversity of HLA molecules in the human population. To capitalize on such “Big Data” the development of computational methods as well as new data repositories will be essential in order to automate the annotation, storage and sharing of large MHC peptidomic datasets. Currently, sequences of eluted peptides can be uploaded and shared through the public immune epitope database (122, 153). On the other hand, the original raw MS files are stored in separate repositories (e.g. PeptideAtlas, PRIDE PRoteomics IDentifications (PRIDE), CHORUS) and more recently, the SWATHAtlas database (82, 140). Ideally, this information should be integrated and centralized within the same database. Genomic information should also be included as this type of information is now essential for the identification of tumor-specific mutant MHC class I peptides, and eventually, for the detection of strain-specific or drug-resistant-specific MHC peptides encoded by pathogen genomes. Such resources would also help to further improve the computational predictability and annotation of MHC peptides, class II in particular. The emerging proteogenomics community could contribute importantly to leveraging the existing procedures toward the creation of this comprehensive resource.

The latest MS technique, DIA mass spectrometry exemplified by SWATH-MS, has the power to digitize the immuno-peptidomic content of physical samples (82). In the future, the

aim should be to integrate both immunopeptidomics and T cell-based “Big Data” in order to predict key immunogenic epitopes in cancer and infectious diseases, e.g. with the help of cloud-based machine learning supercomputers (154–157). Although such advanced systems-level approaches could prove to be highly powerful in the future, one has to keep in mind the paramount importance of applying robust protocols for the isolation of MHC-associated peptides, as it crucially influences the specificity and sensitivity of downstream MS analysis (114). In fact, since the early 1990s, little work has been documented for the isolation of MHC peptide ligands. Moreover, the yield of the widely used IP approach was only recently assessed using state-of-the-art MS techniques and was reported to be about 0.5–3%, indicating extreme losses and/or biases during sample preparation (57). As recently shown in the field of proteomics, sample preparation protocols ideally enable all sample processing steps to be carried out in a single tube to minimize sample losses, thereby enhancing sensitivity, throughput, and scalability of peptidomics analyses (158, 159). The development of rapid and efficient sample processing techniques is therefore crucial for the robust analysis of immunopeptidomes and will be necessary to scale up the process and advance the field effectively into routine clinical application.

Acknowledgments—We thank Peter Weber for graphical design. We also thank Nicola Ternette, Stefan Stevanovic, and Hans-Georg Rammensee as well as members of the Aebersold laboratory for insightful discussions.

* E.C. is supported by a Marie Curie Intra-European Fellowship. R.A. acknowledges the following grant support: ERC grant Proteomics v3.0 (ERC-2008-AdG_20080422), ERC Proteomics 4D (670821), and the Swiss National Science Foundation (3100A0–688 107679).

|| To whom correspondence should be addressed: E-mail: caron@imsb.biol.ethz.ch or aebersold@imsb.biol.ethz.ch.

REFERENCES

- Caron, E., Vincent, K., Fortier, M.-H., Laverdure, J.-P., Bramoullé, A., Hardy, M.-P., Voisin, G., Roux, P. P., Lemieux, S., Thibault, P., and Perreault, C. (2011) The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation. *Mol. Syst. Biol.* **7**, 533
- Admon, A., and Bassani-Sternberg, M. (2011) The Human Immunopeptidome Project, a suggestion for yet another postgenome next big thing. *Mol. Cell. Proteomics* **10**, O111.011833
- Berlin, C., Kowalewski, D. J., Schuster, H., Mirza, N., Walz, S., Handel, M., Schmid-Horch, B., Salih, H. R., Kanz, L., Rammensee, H. G., Stevanović, S., and Stickel, J. S. (2014) Mapping the HLA ligandome landscape of acute myeloid leukemia: A targeted approach toward peptide-based immunotherapy. *Leukemia* **29**, 647–659
- Kowalewski, D. J., Schuster, H., Backert, L., Berlin, C., Kahn, S., Kanz, L., Salih, H. R., Rammensee, H. G., Stevanović, S., and Stickel, J. S. (2015) HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). *Proc. Natl. Acad. Sci. U.S.A.* **112**, E166–175
- Granados, D. P., Sriranganadane, D., Daouda, T., Zieger, A., Laumont, C. M., Caron-Lizotte, O., Boucher, G., Hardy, M. P., Gendron, P., Côté, C., Lemieux, S., Thibault, P., and Perreault, C. (2014) Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides. *Nat. Commun.* **5**, 3600
- Bassani-Sternberg, M., Pletscher-Frankild, S., Jensen, L. J., and Mann, M. (2015) Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. *Mol. Cell. Proteomics* **14**, 658–673
- Hickman, H. D., and Yewdell, J. W. (2010) Mining the plasma immunopeptidome for cancer peptides as biomarkers and beyond. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 18747–18748
- Dudek, N. L., Tan, C. T., Gorasia, D. G., Croft, N. P., Lling, P. T., and Purcell, A. W. (2012) Constitutive and inflammatory immunopeptidome of pancreatic β -cells. *Diabetes* **6**, 3018–3025
- Schellens, I. M. M., Hoof, I., Meiring, H. D., Spijkers, S. N., Poelen, M. C., van Gaans-van den Brink, J. A., van der Poel, K., Costa, A. I., van Els, C. A., van Baarle, D., and Keşmir, C. (2015) Comprehensive analysis of the naturally processed peptide repertoire: Differences between HLA-A and B in the immunopeptidome. *PLoS ONE* **10**, e0136417
- Caron, E., Charbonneau, R., Huppé, G., Brochu, S., and Perreault, C. (2005) The structure and location of SIMP/STT3B account for its prominent imprint on the MHC I immunopeptidome. *Int. Immunol.* **17**, 1583–1596
- Giam, K., Ayala-Perez, R., Illing, P. T., Schittenhelm, R. B., Croft, N. P., Purcell, A. W., and Dudek, N. L. (2015) A comprehensive analysis of peptides presented by HLA-A1. *Tissue Antigens* **85**, 492–496
- Roche, P. A., and Furuta, K. (2015) The ins and outs of MHC class II-mediated antigen processing and presentation. *Nat. Rev. Immunol.* **15**, 203–216
- Cresswell, P., Ackerman, A. L., Giodini, A., Peaper, D. R., and Wearsch, P. A. (2005) Mechanisms of MHC class I-restricted antigen processing and cross-presentation. *Immunol. Rev.* **207**, 145–157
- Rist, M. J., Theodoros, A., Croft, N. P., Neller, M. A., Welland, A., Chen, Z., Sullivan, L. C., Burrows, J. M., Miles, J. J., Brennan, R. M., Gras, S., Khanna, R., Brooks, A. G., McCluskey, J., Purcell, A. W., Rossjohn, J., and Burrows, S. R. (2013) HLA peptide length preferences control CD8⁺ T cell responses. *J. Immunol.* **191**, 561–571
- Burrows, J. M., Bell, M. J., Brennan, R., Miles, J. J., Khanna, R., and Burrows, S. R. (2008) Preferential binding of unusually long peptides to MHC class I and its influence on the selection of target peptides for T cell recognition. *Mol. Immunol.* **45**, 1818–1824
- Kløverpris, H. N., Stryhn, A., Harndahl, M., Payne, R., Towers, G. J., Chen, F., Riddell, L., Walker, B. D., Ndung'u, T., Leslie, A., Buus, S., and Goulder, P. (2013) HLA-specific intracellular epitope processing shapes an immunodominance pattern for HLA-B*57 that is distinct from HLA-B*58:01. *J. Virol.* **87**, 10889–10894
- Bell, M. J., Burrows, J. M., Brennan, R., Miles, J. J., Tellam, J., McCluskey, J., Rossjohn, J., Khanna, R., and Burrows, S. R. (2009) The peptide length specificity of some HLA class I alleles is very broad and includes peptides of up to 25 amino acids in length. *Mol. Immunol.* **46**, 1911–1917
- Shastri, N., Schwab, S., and Serwold, T. (2002) Producing nature's gene-chips: The generation of peptides for display by MHC class I molecules. *Annu. Rev. Immunol.* **20**, 463–493
- Kambayashi, T., and Laufer, T. M. (2014) Atypical MHC class II-expressing antigen-presenting cells: Can anything replace a dendritic cell? *Nat. Rev. Immunol.* **14**, 719–730
- Marsh, S., Parham, P., and Barber, L. D. (2000) *The HLA factsBook*. Academic Press, London. 416 pp.
- Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., and Wiley, D. C. (1987) The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. *Nature* **329**, 512–518
- Garrett, T. P., Saper, M. A., Bjorkman, P. J., Strominger, J. L., and Wiley, D. C. (1989) Specificity pockets for the side chains of peptide antigens in HLA-Aw68. *Nature* **342**, 692–696
- Falk, K., Rötzschke, O., Stevanović, S., Jung, G., and Rammensee, H. G. (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. *Nature* **351**, 290–296
- Lazoura, E., Lodding, J., Farrugia, W., Day, S., Ramsland, P. A., and Apostolopoulos, V. (2009) Non-canonical anchor motif peptides bound to MHC class I induce cellular responses. *Mol. Immunol.* **46**, 1171–1178
- Cole, D. K. (2015) The ultimate mix and match: Making sense of HLA alleles and peptide repertoires. *Immunol. Cell Biol.* **93**, 515–516
- Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E., and Engelhard, V. H. (1992) Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by

- mass spectrometry. *Science* **255**, 1261–1263
27. Croft, N. P., Smith, S. A., Wong, Y. C., Tan, C. T., Dudek, N. L., Flesch, I. E., Lin, L. C., Tschärke, D. C., and Purcell, A. W. (2013) Kinetics of antigen expression and epitope presentation during virus infection. *PLoS Pathog.* **9**, e1003129
 28. Thommen, D. S., Schuster, H., Keller, M., Kapoor, S., Weinzierl, A. O., Chennakesava, C. S., Wang, X., Rohrer, L., von Eckardstein, A., Stevanovic, S., and Biedermann, B. C. (2012) Two preferentially expressed proteins protect vascular endothelial cells from an attack by peptide-specific CTL. *J. Immunol.* **188**, 5283–5292
 29. Apps, R., Meng, Z., Del Prete, G. Q., Lifson, J. D., Zhou, M., and Carington, M. (2015) Relative expression levels of the HLA class-I proteins in normal and HIV-infected cells. *J. Immunol.* **194**, 3594–3600
 30. Scull, K. E., Dudek, N. L., Corbett, A. J., Ramarathinam, S. H., Gorasia, D. G., Williamson, N. A., and Purcell, A. W. (2012) Secreted HLA recapitulates the immunoepitidome and allows in-depth coverage of HLA A*02:01 ligands. *Mol. Immunol.* **51**, 136–142
 31. Hickman, H. D., Luis, A. D., Buchli, R., Few, S. R., Sathiamurthy, M., VanGundy, R. S., Giberson, C. F., and Hildebrand, W. H. (2004) Toward a definition of self: Proteomic evaluation of the class I peptide repertoire. *J. Immunol.* **172**, 2944–2952
 32. Buchsbaum, S., Barnea, E., Dassau, L., Beer, I., Milner, E., and Admon, A. (2003) Large-scale analysis of HLA peptides presented by HLA-Cw4. *Immunogenetics* **55**, 172–176
 33. Hawkins, O. E., Vangundy, R. S., Eckerd, A. M., Bardet, W., Buchli, R., Weidanz, J. A., and Hildebrand, W. H. (2008) Identification of breast cancer peptide epitopes presented by HLA-A*0201. *J. Proteome Res.* **7**, 1445–1457
 34. Ben Dror, L., Barnea, E., Beer, I., Mann, M., and Admon, A. (2010) The HLA-B* 2705 peptidome. *Arthritis Rheum.* **62**, 420–429
 35. Marcilla, M., Alpizar, A., Lombardía, M., Ramos-Fernandez, A., Ramos, M., and Albar, J. P. (2014) Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue. *Mol. Cell. Proteomics* **13**, 462–474
 36. Schittenhelm, R. B., Lim Kam Sian, T. C. C., Wilmann, P. G., Dudek, N. L., and Purcell, A. W. (2014) Revisiting the arthritogenic peptide theory: Quantitative not qualitative changes in the peptide repertoire of HLA-B27 allotypes. *Arthritis Rheum.* **67**, 702–713
 37. Tan, C. T., Croft, N. P., Dudek, N. L., Williamson, N. A., and Purcell, A. W. (2011) Direct quantitation of MHC-bound peptide epitopes by selected reaction monitoring. *Proteomics* **11**, 2336–2340
 38. de Verteuil, D., Muratore-Schroeder, T. L., Granados, D. P., Fortier, M.-H., Hardy, M.-P., Bramoullé, A., Caron, E., Vincent, K., Mader, S., Lemieux, S., Thibault, P., and Perreault, C. (2010) Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. *Mol. Cell. Proteomics* **9**, 2034–2047
 39. Fortier, M. H., Caron, E., Hardy, M. P., Voisin, G., Lemieux, S., Perreault, C., and Thibault, P. (2008) The MHC class I peptide repertoire is molded by the transcriptome. *J. Exp. Med.* **205**, 595–610
 40. Bozzacco, L., Yu, H., Zebroski, H. A., Dengjel, J., Deng, H., Mojsov, S., and Steinman, R. M. (2011) Mass spectrometry analysis and quantitation of peptides presented on the MHC II molecules of mouse spleen dendritic cells. *J. Proteome Res.* **10**, 5016–5030
 41. Dutoit, V., Herold-Mende, C., Hilf, N., Schoor, O., Beckhove, P., Bucher, J., Dorsch, K., Flohr, S., Fritsche, J., Lewandrowski, P., Lohr, J., Rammensee, H.-G., Stevanovic, S., Trautwein, C., Vass, V., Walter, S., Walker, P. R., Weinschenk, T., Singh-Jasuja, H., and Dietrich, P.-Y. (2012) Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. *Brain* **135**, 1042–1054
 42. Cresswell, P., Turner, M. J., and Strominger, J. L. (1973) Papain-solubilized HL-A antigens from cultured human lymphocytes contain two peptide fragments. *Proc. Natl. Acad. Sci. U.S.A.* **70**, 1603–1607
 43. Peterson, P. A., Rask, L., and Lindblom, J. B. (1974) Highly purified papain-solubilized HL-A antigens contain beta2-microglobulin. *Proc. Natl. Acad. Sci. U.S.A.* **71**, 35–39
 44. Nathenson, S. G., Uehara, H., Ewenstein, B. M., Kindt, T. J., and Coligan, J. E. (1981) Primary structural: Analysis of the transplantation antigens of the murine H-2 major histocompatibility complex. *Annu. Rev. Biochem.* **50**, 1025–1052
 45. Rötzschke, O., Falk, K., Wallny, H. J., Faath, S., and Rammensee, H. G. (1990) Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. *Science* **249**, 283–287
 46. Rötzschke, O., Falk, K., Deres, K., Schild, H., Norda, M., Metzger, J., Jung, G., and Rammensee, H. G. (1990) Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. *Nature* **348**, 252–254
 47. Falk, K., Rötzschke, O., and Rammensee, H. G. (1990) Cellular peptide composition governed by major histocompatibility complex class I molecules. *Nature* **348**, 248–251
 48. Storkus, W. J., Zeh, H. J., 3rd Salter, R. D., and Lotze, M. T. (1993) Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution. *J. Immunother. Emphasis Tumor Immunol.* **14**, 94–103
 49. Van Bleek, G. M., and Nathenson, S. G. (1990) Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. *Nature* **348**, 213–216
 50. Antwi, K., Hanavan, P. D., Myers, C. E., Ruiz, Y. W., Thompson, E. J., and Lake, D. F. (2009) Proteomic identification of an MHC-binding peptide from pancreas and breast cancer cell lines. *Mol. Immunol.* **46**, 2931–2937
 51. Bassani-Sternberg, M., Pletscher-Frankild, S., Jensen, L. J., and Mann, M. (2015) Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. *Mol. Cell. Proteomics* **14**, 658–673
 52. Bassani-Sternberg, M., Barnea, E., Beer, I., Avivi, I., Katz, T., and Admon, A. (2010) Soluble plasma HLA peptidome as a potential source for cancer biomarkers. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 18769–18776
 53. Kowalewski, D. J., and Stevanović, S. (2013) Biochemical large-scale identification of MHC class I ligands. *Methods Mol. Biol.* **960**, 145–157
 54. Mommen, G. P., Frese, C. K., Meiring, H. D., van Gaans-van den Brink, J., de Jong, A. P., van Els, C. A., and Heck, A. J. (2014) Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (ETHcD). *Proc. Natl. Acad. Sci. U.S.A.* **111**, 4507–4512
 55. Kasuga, K. (2013) Comprehensive analysis of MHC ligands in clinical material by immunoaffinity-mass spectrometry. *Methods Mol. Biol.* **1023**, 203–218
 56. Galati, G., Arcelloni, C., Paroni, R., Heltai, S., Rovere, P., Rugarli, C., and Manfredi, A. A. (1997) Quantitative cytometry of MHC class I digestion from living cells. *Cytometry* **27**, 77–83
 57. Hassan, C., Kester, M. G., Oudgenoeg, G., de Ru, A. H., Janssen, G. M., Drijfhout, J. W., Spaapen, R. M., Jiménez, C. R., Heemskerck, M. H., Falkenburg, J. H., and van Veelen, P. A. (2014) Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes. *J. Proteomics* **109**, 240–244
 58. Domon, B., and Aebersold, R. (2006) Mass spectrometry and protein analysis. *Science* **312**, 212–217
 59. Aebersold, R., and Mann, M. (2003) Mass spectrometry-based proteomics. *Nature* **422**, 198–207
 60. Leitner, A., and Aebersold, R. (2013) SnapShot: Mass spectrometry for protein and proteome analyses. *Cell* **154**, 252–252.e1
 61. Granados, D. P., Laumont, C. M., Thibault, P., and Perreault, C. (2015) The nature of self for T cells—A systems-level perspective. *Curr. Opin. Immunol.* **34**, 1–8
 62. Mester, G., Hoffmann, V., and Stevanović, S. (2011) Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands. *Cell. Mol. Life Sci.* **68**, 1521–1532
 63. Hillen, N., and Stevanovic, S. (2006) Contribution of mass spectrometry-based proteomics to immunology. *Expert Rev. Proteomics* **3**, 653–664
 64. Picotti, P., Bodenmiller, B., and Aebersold, R. (2013) Proteomics meets the scientific method. *Nat. Methods* **10**, 24–27
 65. Liu, Y., Hüttenhain, R., Collins, B., and Aebersold, R. (2013) Mass spectrometric protein maps for biomarker discovery and clinical research. *Expert Rev. Mol. Diagn.* **13**, 811–825
 66. Sajic, T., Liu, Y., and Aebersold, R. (2015) Using data-independent, high resolution mass spectrometry in protein biomarker research: Perspectives and clinical applications. *Proteomics Clin. Appl.* **9**, 307–321
 67. Michalski, A., Damoc, E., Hauschild, J. P., Lange, O., Wieghaus, A., Makarov, A., Nagaraj, N., Cox, J., Mann, M., and Horning, S. (2011) Mass spectrometry-based proteomics using Q Exactive, a high-performance benchtop quadrupole orbitrap mass spectrometer. *Mol. Cell.*

- Proteomics* **10**, M111.011015
68. Andrews, G. L., Simons, B. L., Young, J. B., Hawkrigde, A. M., and Muddiman, D. C. (2011) Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass spectrometer (TripleTOF 5600). *Anal. Chem.* **83**, 5442–5446
 69. Nesvizhskii, A. I. (2010) A survey of computational methods and error rate estimation procedures for peptide and protein identification in shotgun proteomics. *J. Proteomics* **73**, 2092–2123
 70. Shteynberg, D., Nesvizhskii, A. I., Moritz, R. L., and Deutsch, E. W. (2013) Combining results of multiple search engines in proteomics. *Mol. Cell. Proteomics* **12**, 2383–2393
 71. Escobar, H., Reyes-Vargas, E., Jensen, P. E., Delgado, J. C., and Crockett, D. K. (2011) Utility of characteristic QTOF MS/MS fragmentation for MHC class I peptides. *J. Proteome Res.* **10**, 2494–2507
 72. Ternette, N., Block, P., Sánchez-Bernabéu, Á., Borthwick, N., Pappalardo, E., Abdul-Jawad, S., Ondondo, B., Charles, P. D., Dorrell, L., Kessler, B. M., and Hanke, T. (2015) Early kinetics of HLA class I-associated peptidome of MVA.HIVconsv-infected cells. *J. Virol.* **89**, 5760–5771
 73. Hahne, H., Pachi, F., Ruprecht, B., Maier, S. K., Klaeger, S., Helm, D., Médard, G. M. E., Wilm, M., Lemeer, S., and Kuster, B. (2013) DMSO enhances electrospray response, boosting sensitivity of proteomic experiments. *Nat. Methods* **10**, 989–991
 74. Frese, C. K., Altelaar, A. F., van den Toorn, H., Nolting, D., Griep-Raming, J., Heck, A. J., and Mohammed, S. (2012) Toward full peptide sequence coverage by dual fragmentation combining electron-transfer and higher-energy collision dissociation tandem mass spectrometry. *Anal. Chem.* **84**, 9668–9673
 75. Frese, C. K., Zhou, H., Taus, T., Altelaar, A. F., Mechtler, K., Heck, A. J., and Mohammed, S. (2013) Unambiguous phosphosite localization using electron-transfer/higher-energy collision dissociation (EThcD). *J. Proteome Res.* **12**, 1520–1525
 76. Käll, L., Canterbury, J. D., Weston, J., Noble, W. S., and MacCoss, M. J. (2007) Semi-supervised learning for peptide identification from shotgun proteomics datasets. *Nat. Methods* **4**, 923–925
 77. Elias, J. E., and Gygi, S. P. (2007) Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. *Nat. Methods* **4**, 207–214
 78. Michalski, A., Cox, J., and Mann, M. (2011) More than 100,000 detectable peptide species elute in single shotgun proteomics runs but the majority is inaccessible to data-dependent LC-MS/MS. *J. Proteome Res.* **10**, 1785–1793
 79. Tabb, D. L., Vega-Montoto, L., Rudnick, P. A., Variyath, A. M., Ham, A.-J., Bunk, D. M., Kilpatrick, L. E., Billheimer, D. D., Blackman, R. K., Cardasis, H. L., Carr, S. A., Clauser, K. R., Jaffe, J. D., Kowalski, K. A., Neubert, T. A., Regnier, F. E., Schilling, B., Tegeler, T. J., Wang, M., Wang, P., Whiteaker, J. R., Zimmerman, L. J., Fisher, S. J., Gibson, B. W., Kinsinger, C. R., Mesri, M., Rodriguez, H., Stein, S. E., Tempst, P., Paulovich, A. G., Liebler, D. C., and Spiegelman, C. (2010) Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. *J. Proteome Res.* **9**, 761–776
 80. Wolf-Yadlin, A., Hautaniemi, S., Lauffenburger, D. A., and White, F. M. (2007) Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 5860–5865
 81. Liu, H., Sadygov, R. G., and Yates, 3rd, J. R. (2004) A model for random sampling and estimation of relative protein abundance in shotgun proteomics. *Anal. Chem.* **76**, 4193–4201
 82. Caron, E., Espona, L., Kowalewski, D. J., Schuster, H., Ternette, N., Alpizar, A., Schittenhelm, R. B., Ramarathinam, S. H., Lindestam Arlehamm, C. S., Chiek Koh, C., Gillet, L. C., Rabsteyn, A., Navarro, P., Kim, S., Lam, H., Sturm, T., Marcilla, M., Sette, A., Campbell, D. S., Deutsch, E. W., Moritz, R. L., Purcell, A. W., Rammensee, H.-G., Stevanovic, S., and Aebersold, R. (2015) An open-source computational and data resource to analyze digital maps of immunopeptidomes. *eLife* **4**, e07661
 83. Marx, V. (2013) Targeted proteomics. *Nat. Methods* **10**, 19–22
 84. Picotti, P., and Aebersold, R. (2012) Selected reaction monitoring-based proteomics: Workflows, potential, pitfalls and future directions. *Nat. Methods* **9**, 555–566
 85. Gallien, S., Bourmaud, A., Kim, S. Y., and Domon, B. (2014) Technical considerations for large-scale parallel reaction monitoring analysis. *J. Proteomics* **100**, 147–159
 86. Peterson, A. C., Russell, J. D., Bailey, D. J., Westphall, M. S., and Coon, J. J. (2012) Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. *Mol. Cell. Proteomics* **11**, 1475–1488
 87. Hogan, K. T., Sutton, J. N., Chu, K. U., Busby, J. A., Shabanowitz, J., Hunt, D. F., and Slingsluff, C. L., Jr. (2004) Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. *Cancer Immunol. Immunother.* **54**, 359–371
 88. Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., Mulder, G. E., Toebes, M., Vesely, M. D., Lam, S. S., Korman, A. J., Allison, J. P., Freeman, G. J., Sharpe, A. H., Pearce, E. L., Schumacher, T. N., Abersold, R., Rammensee, H.-G., Melief, C. J., Mardis, E. R., Gillanders, W. E., Artyomov, M. N., and Schreiber, R. D. (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. *Nature* **515**, 577–581
 89. MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., Finney, G. L., Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., and MacCoss, M. J. (2010) Skyline: An open source document editor for creating and analyzing targeted proteomics experiments. *Bioinformatics* **26**, 966–968
 90. Reiter, L., Rinner, O., Picotti, P., Hüttenhain, R., Beck, M., Brusniak, M.-Y., Hengartner, M. O., and Aebersold, R. (2011) mProphet: Automated data processing and statistical validation for large-scale SRM experiments. *Nat. Methods* **8**, 430–435
 91. Surinova, S., Hüttenhain, R., Chang, C. Y., Espona, L., Vitek, O., and Aebersold, R. (2013) Automated selected reaction monitoring data analysis workflow for large-scale targeted proteomic studies. *Nat. Protoc.* **8**, 1602–1619
 92. Picotti, P., Rinner, O., Stallmach, R., Dautel, F., Farrah, T., Domon, B., Wenschuh, H., and Aebersold, R. (2010) High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. *Nat. Methods* **7**, 43–46
 93. Picotti, P., Lam, H., Campbell, D., Deutsch, E. W., Mirzaei, H., Ranish, J., Domon, B., and Aebersold, R. (2008) A database of mass spectrometric assays for the yeast proteome. *Nat. Methods* **5**, 913–914
 94. Lange, V., Picotti, P., Domon, B., and Aebersold, R. (2008) Selected reaction monitoring for quantitative proteomics: A tutorial. *Mol. Syst. Biol.* **4**, 222
 95. Lesur, A., and Domon, B. (2015) Advances in high-resolution accurate mass spectrometry application to targeted proteomics. *Proteomics* **15**, 880–890
 96. MacLean, B., Tomazela, D. M., Abbatiello, S. E., Zhang, S., Whiteaker, J. R., Paulovich, A. G., Carr, S. A., and MacCoss, M. J. (2010) Effect of collision energy optimization on the measurement of peptides by selected reaction monitoring (SRM) mass spectrometry. *Anal. Chem.* **82**, 10116–10124
 97. Holstein Sherwood, C. A., Gafken, P. R., and Martin, D. B. (2011) Collision energy optimization of b- and y-ions for multiple reaction monitoring mass spectrometry. *J. Proteome Res.* **10**, 231–240
 98. Sherwood, C. A., Eastham, A., Lee, L. W., Risler, J., Mirzaei, H., Falkner, J. A., and Martin, D. B. (2009) Rapid optimization of MRM-MS instrument parameters by subtle alteration of precursor and product *m/z* targets. *J. Proteome Res.* **8**, 3746–3751
 99. Kennedy, J. J., Abbatiello, S. E., Kim, K., Yan, P., Whiteaker, J. R., Lin, C., Kim, J. S., Zhang, Y., Wang, X., Ivey, R. G., Zhao, L., Min, H., Lee, Y., Yu, M. H., Yang, E. G., Lee, C., Wang, P., Rodriguez, H., Kim, Y., Carr, S. A., and Paulovich, A. G. (2014) Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. *Nat. Methods* **11**, 149–155
 100. Gallien, S., Duriez, E., Demeure, K., and Domon, B. (2013) Selectivity of LC-MS/MS analysis: Implication for proteomics experiments. *J. Proteomics* **81**, 148–158
 101. Schiffmann, C., Hansen, R., Baumann, S., Kublik, A., Nielsen, P. H., Adrian, L., von Bergen, M., Jehmlich, N., and Seifert, J. (2014) Comparison of targeted peptide quantification assays for reductive dehalogenases by selective reaction monitoring (SRM) and precursor reaction monitoring (PRM). *Anal. Bioanal. Chem.* **406**, 283–291
 102. Ronsein, G. E., Pamir, N., von Haller, P. D., Kim, D. S., Oda, M. N., Jarvik, G. P., Vaisar, T., and Heinecke, J. W. (2015) Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable lin-

- earity, dynamic range and precision for targeted quantitative HDL proteomics. *J. Proteomics* **113**, 388–399
103. Gillet, L. C., Navarro, P., Tate, S., Röst, H., Selevsek, N., Reiter, L., Bonner, R., and Aebersold, R. (2012) Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: A new concept for consistent and accurate proteome analysis. *Mol. Cell. Proteomics* **11**, O111.016717
 104. Venable, J. D., Dong, M. Q., Wohlschlegel, J., Dillin, A., and Yates, J. R. (2004) Automated approach for quantitative analysis of complex peptide mixtures from tandem mass spectra. *Nat. Methods* **1**, 39–45
 105. Chapman, J. D., Goodlett, D. R., and Masselon, C. D. (2014) Multiplexed and data-independent tandem mass spectrometry for global proteome profiling. *Mass Spectrom. Rev.* **33**, 452–470
 106. Distler, U., Kuharev, J., and Tenzer, S. (2014) Biomedical applications of ion mobility-enhanced data-independent acquisition-based label-free quantitative proteomics. *Expert Rev. Proteomics* **11**, 675–684
 107. Law, K. P., and Lim, Y. P. (2013) Recent advances in mass spectrometry: Data independent analysis and hyper reaction monitoring. *Expert Rev. Proteomics* **10**, 551–566
 108. Röst, H. L., Rosenberger, G., Navarro, P., Gillet, L., Miladinović, S. M., Schubert, O. T., Wolski, W., Collins, B. C., Malmström, J., Malmström, L., and Aebersold, R. (2014) OpenSWATH enables automated, targeted analysis of data-independent acquisition MS data. *Nat. Biotechnol.* **32**, 219–223
 109. Rosenberger, G., Koh, C. C., Guo, T., Röst, H. L., Kouvonen, P., Collins, B. C., Heusel, M., Liu, Y., Caron, E., Vichalkovski, A., Faini, M., Schubert, O. T., Faridi, P., Ehardt, H. A., Matondo, M., Lam, H., Bader, S. L., Campbell, D. S., Deutsch, E. W., Moritz, R. L., Tate, S., and Aebersold, R. (2014) A repository of assays to quantify 10,000 human proteins by SWATH-MS. *Sci. Data* **1**, 140031
 110. Collins, B. C., Gillet, L. C., Rosenberger, G., Röst, H. L., Vichalkovski, A., Gstaiger, M., and Aebersold, R. (2013) Quantifying protein interaction dynamics by SWATH mass spectrometry: Application to the 14–3-3 system. *Nat. Methods* **10**, 1246–1253
 111. Schubert, O. T., Gillet, L. C., Collins, B. C., Navarro, P., Rosenberger, G., Wolski, W. E., Lam, H., Amodei, D., Mallick, P., MacLean, B., and Aebersold, R. (2015) Building high-quality assay libraries for targeted analysis of SWATH MS data. *Nat. Protoc.* **10**, 426–441
 112. Liu, Y., Chen, J., Sethi, A., Li, Q. K., Chen, L., Collins, B., Gillet, L. C., Wollscheid, B., Zhang, H., and Aebersold, R. (2014) Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. *Mol. Cell. Proteomics* **13**, 1453–1768
 113. Liu, Y., Buil, A., Collins, B. C., Gillet, L. C., Blum, L. C., Cheng, L. Y., Vitek, O., Mouritsen, J., Lachance, G., Spector, T. D., Dermitzakis, E. T., and Aebersold, R. (2015) Quantitative variability of 342 plasma proteins in a human twin population. *Mol. Syst. Biol.* **11**, 786–786
 114. Guo, T., Kouvonen, P., Koh, C. C., Gillet, L. C., Wolski, W. E., Röst, H. L., Rosenberger, G., Collins, B. C., Blum, L. C., Gillessen, S., Joergler, M., Jochum, W., and Aebersold, R. (2015) Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. *Nat. Med.* **21**, 407–413
 115. Selevsek, N., Chang, C. Y., Gillet, L. C., Navarro, P., Bernhardt, O. M., Reiter, L., Cheng, L.-Y., Vitek, O., and Aebersold, R. (2015) Reproducible and consistent quantification of the *Saccharomyces cerevisiae* proteome by SWATH-mass spectrometry. *Mol. Cell. Proteomics* **14**, 739–749
 116. Schubert, O. T., Ludwig, C., Kogadeeva, M., Zimmermann, M., Rosenberger, G., Gengenbacher, M., Gillet, L. C., Ben C Collins, Röst, H. L., Kaufmann, S. H., Sauer, U., and Aebersold, R. (2015) Absolute proteome composition and dynamics during dormancy and resuscitation of mycobacterium tuberculosis. *Cell Host Microbe* **18**, 96–108
 117. Bruderer, R., Bernhardt, O. M., Gandhi, T., Miladinović, S. M., Cheng, L.-Y., Messner, S., Ehrenberger, T., Zanotelli, V., Butscheid, Y., Escher, C., Vitek, O., Rinner, O., and Reiter, L. (2015) Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues. *Mol. Cell. Proteomics* **14**, 1400–1410
 118. Toprak, U. H., Gillet, L. C., Maiolica, A., Navarro, P., Leitner, A., and Aebersold, R. (2014) Conserved peptide fragmentation as a benchmarking tool for mass spectrometers and a discriminating feature for targeted proteomics. *Mol. Cell. Proteomics* **13**, 2056–2071
 119. Tsou, C.-C., Avtonomov, D., Larsen, B., Tucholska, M., Choi, H., Gingras, A.-C., and Nesvizhskii, A. I. (2015) DIA-umpire: Comprehensive computational framework for data-independent acquisition proteomics. *Nat. Methods* **12**, 258–264
 120. Rammensee, H., Bachmann, J., Emmerich, N. P., Bachor, O. A., and Stevanović, S. (1999) SYFPEITHI: Database for MHC ligands and peptide motifs. *Immunogenetics* **50**, 213–219
 121. Karosiene, E., Lundegaard, C., Lund, O., and Nielsen, M. (2012) NetMHCcons: A consensus method for the major histocompatibility complex class I predictions. *Immunogenetics* **64**, 177–186
 122. Peters, B., Bui, H.-H., Frankild, S., Nielsen, M., Lundegaard, C., Kostem, E., Basch, D., Lamberth, K., Harndahl, M., Fleri, W., Wilson, S. S., Sidney, J., Lund, O., Buus, S., and Sette, A. (2006) A community resource benchmarking predictions of peptide binding to MHC-I molecules. *PLoS Comp. Biol.* **2**, e65
 123. Cobbold, M., De La Peña, H., Norris, A., Polefrone, J. M., Qian, J., English, A. M., Cummings, K. L., Penny, S., Turner, J. E., Cottine, J., Abelin, J. G., Malaker, S. A., Zurling, A. L., Huang, H. W., Goodyear, O., Freeman, S. D., Shabanowitz, J., Pratt, G., Craddock, C., Williams, M. E., Hunt, D. F., and Engelhard, V. H. (2013) MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. *Sci. Transl. Med.* **5**, 203ra125
 124. Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., Hilf, N., Schoor, O., Fritsche, J., Mahr, A., Maurer, D., Vass, V., Trautwein, C., Lewandowski, P., Flohr, C., Pohla, H., Stanczak, J. J., Bronte, V., Mandruzzato, S., Biedermann, T., Pawelec, G., Derhovanessian, E., Yamagishi, H., Miki, T., Hongo, F., Takaha, N., Hirakawa, K., Tanaka, H., Stevanovic, S., Frisch, J., Mayer-Mokler, A., Kirner, A., Rammensee, H.-G., Reinhardt, C., and Singh-Jasuja, H. (2012) Multipetide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. *Nat. Med.* **18**, 1254–1261
 125. Moutaftsi, M., Peters, B., Pasquetto, V., Tschärke, D. C., Sidney, J., Bui, H.-H., Grey, H., and Sette, A. (2006) A consensus epitope prediction approach identifies the breadth of murine TCD8+ cell responses to vaccinia virus. *Nat. Biotechnol.* **24**, 817–819
 126. Caron, E., Vincent, K., Fortier, M. H., Laverdure, J.-P., Bramoullé, A., Hardy, M. P., Voisin, G., Roux, P. P., Lemieux, S., Thibault, P., and Perreault, C. (2011) The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation. *Mol. Syst. Biol.* **7**, 533
 127. Weinzierl, A. O., Lemmel, C., Schoor, O., Müller, M., Krüger, T., Wernet, D., Hennenlotter, J., Stenzl, A., Klingel, K., Rammensee, H. G., and Stevanovic, S. (2007) Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. *Mol. Cell. Proteomics* **6**, 102–113
 128. Granados, D. P., Yahyaoui, W., Laumont, C. M., Daouda, T., Muratore-Schroeder, T. L., Côté, C., Laverdure, J.-P., Lemieux, S., Thibault, P., and Perreault, C. (2012) MHC I-associated peptides preferentially derive from transcripts bearing miRNA response elements. *Blood* **119**, e181–91
 129. Milner, E., Barnea, E., Beer, I., and Admon, A. (2006) The turnover kinetics of major histocompatibility complex peptides of human cancer cells. *Mol. Cell. Proteomics* **5**, 357–365
 130. Milner, E., Gutter-Kapon, L., Bassani-Strenberg, M., Barnea, E., Beer, I., and Admon, A. (2013) The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome. *Mol. Cell. Proteomics* **12**, 1853–1864
 131. Bourdetsky, D., Schmelzer, C. E., and Admon, A. (2014) The nature and extent of contributions by defective ribosome products to the HLA peptidome. *Proc. Natl. Acad. Sci. U.S.A.* **111**, E1591–E1599
 132. Johnstone, C., Lorente, E., Barriga, A., Barnea, E., Infantes, S., Lemonnier, F. A., David, C. S., Admon, A., and López, D. (2015) The viral transcription group determines the HLA class I cellular immune response against human respiratory syncytial virus. *Mol. Cell. Proteomics* **14**, 893–904
 133. Hassan, C., Kester, M. G., de Ru, A. H., Hombrink, P., Drijfhout, J. W., Nijveen, H., Leunissen, J. A., Heemskerck, M. H., Falkenburg, J. H., and van Veelen, P. A. (2013) The human leukocyte antigen-presented ligandome of B lymphocytes. *Mol. Cell. Proteomics* **12**, 1829–1843
 134. Trujillo, J. A., Croft, N. P., Dudek, N. L., Channappanavar, R., Theodosis,

- A., Webb, A. I., Dunstone, M. A., Illing, P. T., Butler, N. S., Fett, C., Tschärke, D. C., Rossjohn, J., Perlman, S., and Purcell, A. W. (2014) The cellular redox environment alters antigen presentation. *J. Biol. Chem.* **289**, 27979–27991
135. Reits, E. A., Hodge, J. W., Herberts, C. A., Grootuis, T. A., Chakraborty, M., Wansley, E. K., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F. A., Spits, H., Schlom, J., van Veelen, P., and Neefjes, J. J. (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. *J. Exp. Med.* **203**, 1259–1271
136. Adamopoulou, E., Tenzer, S., Hillen, N., Klug, P., Rota, I. A., Tietz, S., Gebhardt, M., Stevanovic, S., Schild, H., Tolosa, E., Melms, A., and Stoeckle, C. (2013) Exploring the MHC-peptide matrix of central tolerance in the human thymus. *Nat. Commun.* **4**, 2039
137. Couzin-Frankel, J. (2013) Breakthrough of the year 2013. Cancer immunotherapy. *Science* **342**, 1432–1433
138. Sharma, P., and Allison, J. P. (2015) The future of immune checkpoint therapy. *Science* **348**, 56–61
139. Alfaro, J. A., Sinha, A., Kislinger, T., and Boutros, P. C. (2014) Onco-proteogenomics: Cancer proteomics joins forces with genomics. *Nat. Methods* **11**, 1107–1113
140. Nesvizhskii, A. I. (2014) Proteogenomics: Concepts, applications and computational strategies. *Nat. Methods* **11**, 1114–1125
141. Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., Modrusan, Z., Mellman, I., Lill, J. R., and Delamarre, L. (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. *Nature* **515**, 572–576
142. Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W. R., Hildebrand, W. H., Mardis, E. R., and Linette, G. P. (2015) A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. *Science* **348**, 803–808
143. Hombrink, P., Hassan, C., Kester, M. G., de Ru, A. H., van Bergen, C. A., Nijveen, H., Drijfhout, J. W., Falkenburg, J. H., Heemskerk, M. H., and van Veelen, P. A. (2013) Discovery of T cell epitopes implementing HLA-peptidomics into a reverse immunology approach. *J. Immunol.* **190**, 3869–3877
144. Hombrink, P., Hassan, C., Kester, M. G., Jahn, L., Pont, M. J., de Ru, A. H., van Bergen, C. A., Griffioen, M., Falkenburg, J. H., van Veelen, P. A., and Heemskerk, M. H. (2015) Identification of biological relevant minor histocompatibility antigens within the B-lymphocyte derived HLA-ligandome using a reverse immunology approach. *Clin. Cancer Res.* **21**, 2177–2186
145. Schumacher, T. N., Keşmir, C., and van Buuren, M. M. (2015) Biomarkers in cancer immunotherapy. *Cancer Cell* **27**, 12–14
146. Schumacher, T. N., and Schreiber, R. D. (2015) Neoantigens in cancer immunotherapy. *Science* **348**, 69–74
147. Gilchuk, P., Spencer, C. T., Conant, S. B., Hill, T., Gray, J. J., Niu, X., Zheng, M., Erickson, J. J., Boyd, K. L., McAfee, K. J., Oseroff, C., Hadrup, S. R., Bennink, J. R., Hildebrand, W., Edwards, K. M., Crowe, J. E., Jr., Williams, J. V., Buus, S., Sette, A., Schumacher, T. N., Link, A. J., and Joyce, S. (2013) Discovering naturally processed antigenic determinants that confer protective T cell immunity. *J. Clin. Invest.* **123**, 1976–1987
148. Ovsyannikova, I. G., Johnson, K. L., 3rd, Bergen, H. R., and Poland, G. A. (2007) Mass spectrometry and peptide-based vaccine development. *Clin. Pharmacol. Ther.* **82**, 644–652
149. Yaciuk, J. C., Skaley, M., Bardet, W., Schafer, F., Mojsilovic, D., Cate, S., Stewart, C. J., McMurtrey, C., Jackson, K. W., Buchli, R., Olvera, A., Cedeño, S., Plana, M., Mothe, B., Brander, C., West, J. T., and Hildebrand, W. H. (2014) Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells. *J. Virol.* **88**, 12992–13004
150. Wölk, B., Trautwein, C., Büchele, B., Kersting, N., Blum, H. E., Ramensee, H. G., Cerny, A., Stevanovic, S., Moradpour, D., and Brass, V. (2012) Identification of naturally processed hepatitis C virus-derived major histocompatibility complex class I ligands. *PLoS ONE* **7**, e29286
151. Riemer, A. B., Keskin, D. B., Zhang, G., Handley, M., Anderson, K. S., Brusic, V., Reinhold, B., and Reinherz, E. L. (2010) A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. *J. Biol. Chem.* **285**, 29608–29622
152. Kumari, S., Wälchli, S., Fallang, L.-E., Yang, W., Lund-Johansen, F., Schumacher, T. N., and Olweus, J. (2014) Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 403–408
153. Salimi, N., Fleri, W., Peters, B., and Sette, A. (2012) The immune epitope database: A historical retrospective of the first decade. *Immunology* **137**, 117–123
154. Kelchtermans, P., Bittremieux, W., De Grave, K., Degroev, S., Ramon, J., Laukens, K., Valkenburg, D., Barsnes, H., and Martens, L. (2014) Machine learning applications in proteomics research: How the past can boost the future. *Proteomics* **14**, 353–366
155. Lynch, C. (2008) Big Data: How do your data grow? *Nature* **455**, 28–29
156. Stein, L. D., Knoppers, B. M., Campbell, P., Getz, G., and Korb, J. O. (2015) Data analysis: Create a cloud commons. *Nature* **523**, 149–151
157. Schultze, J. L. (2015) Teaching “Big Data” analysis to young immunologists. *Nat. Immunol.* **16**, 902–905
158. Hughes, C. S., Foehr, S., Garfield, D. A., Furlong, E. E., Steinmetz, L. M., and Krijgsveld, J. (2014) Ultrasensitive proteome analysis using paramagnetic bead technology. *Mol. Syst. Biol.* **10**, 757
159. Kanschin, E., and Thibault, P. (2014) Efficient sample processing for proteomics applications—Are we there yet? *Mol. Syst. Biol.* **10**, 758